AZD 2066 single dose formulation and food effect study in healthy volunteers
Study identifier:D0475C00005
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Study Complete
Official Title
A Phase 1, single-center, randomized, open-label, two-way crossover, formulation and food effect study in healthy volunteers, to assess the pharmacokinetics of AZD 2066 after single doses of a new oral solid formulation and an oral solution
Medical condition
Healthy
Phase
Phase 1
Healthy volunteers
Yes
Study drug
AZD2066
Sex
All
Actual Enrollment
20
Study type
Interventional
Age
20 Years - 45 Years
Date
Study Start Date: 01 Apr 2008
Primary Completion Date: 01 Jun 2008
Study Completion Date: 01 Jun 2008
Study design
Allocation: Randomized
Endpoint Classification: Pharmacokinetics Study
Intervention Model: Crossover Assignment
Masking: Open Label
Primary Purpose: Other
Verification:
Verified 01 Nov 2013 by AstraZeneca Pharmaceuticals
Sponsors
AstraZeneca Pharmaceuticals
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|---|
| Experimental: 1 | Drug: AZD2066 single oral dose |
Contacts
Investigators
Principal Investigator
Eleanor Lisbon
Quintiles, Inc. Overland Park, Kansas, USA
